My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Pfizer (NY:PFE)

25.85 +0.05 (+0.19%)

Official Closing Price Updated: 7:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

99 100 Next >

Nvidia’s $100B Bet in OpenAI Pushes Wall Street to Fresh Records ↗

September 23, 2025

Tech did the heavy lifting as Nvidia and Apple dragged indexes over the finish line; gold hit yet another all-time high while oil sagged. The Fed chorus grew louder and more discordant.

Via Chartmill

Topics Economy

Viking Therapeutics Stock Gets Boost From Pfizer-Metsera Deal, Says BTIG — Retail Slams Rivals For Buying ‘Inferior Pipelines’ ↗

September 22, 2025

BTIG said Pfizer’s $7.3 billion Metsera acquisition sharpens its clinical updates and strategic optionality.

Via Stocktwits

Trump Advises Parents To Split Vaccines, Delay Hepatitis B Shots Until Age 12: 'This Is Based On What I Feel' ↗

September 22, 2025

President Donald Trump on Monday offered advice on childhood vaccination schedules, encouraging parents to split up certain immunizations and delay certain others, in sharp contradiction to current...

Via Benzinga

Topics Government

Why BioNTech Stock Bumped Higher Today ↗

September 22, 2025

Investors were cheered by two pieces of good news concerning the biotech's most famous product.

Via The Motley Fool

Pfizer Stock Draws Focus On Report Of $7.3B Deal Plan For Metsera Buyout As Obesity Drug Race With Lilly, Novo Heats Up ↗

September 22, 2025

Via Stocktwits

Curious about the most active S&P500 stocks in today's session? ↗

September 22, 2025

Stay informed about the most active S&P500 stocks in today's session as we take a closer look at what's happening on the US markets on Monday. Discover the stocks that are generating the highest...

Via Chartmill

Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market

September 22, 2025

The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a...

Via MarketMinute

Topics Economy Intellectual Property

MTSR Shares Jump After Pfizer Merger Agreement ↗

September 22, 2025

Metsera stock skyrocketed 62% as Pfizer struck a $4.9 billion acquisition agreement focused on obesity therapies.

Via Talk Markets

Why Pfizer Stock Just Popped ↗

September 22, 2025

Pfizer's own GLP-1 drug candidate failed earlier this year -- so it's buying someone else's.

Via The Motley Fool

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Premier, Inc. (Nasdaq – PINC), Metsera, Inc. (Nasdaq – MTSR), Anywhere Real Estate Inc. (NYSE – HOUS), The ODP Corporation (Nasdaq – ODP)

September 22, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might

September 22, 2025

The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

Gold Gains Over 1%; Quantum Computing Shares Plunge ↗

September 22, 2025

Via Benzinga

IBD 50's Tempus AI Hits Record High On Yet Another FDA Clearance ↗

September 22, 2025

The company is focusing on RNA sequencing as a means of assisting with drug development.

Via Investor's Business Daily

Topics Artificial Intelligence Intellectual Property

Pfizer Claws Deeper Into The Obesity Space With $4.9 Billion Metsera Deal ↗

September 22, 2025

The deal follows two high-profile failures for Pfizer, which is trying to broaden its small pipeline in weight loss.

Via Investor's Business Daily

Pfizer Tries To Revitalize Obesity Portfolio With $5 Billion Matsera Deal ↗

September 22, 2025

Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to its pipeline.

Via Benzinga

3 Dirt-Cheap Stocks to Buy Right Now ↗

September 22, 2025

These stocks share several common denominators, including attractive valuations.

Via The Motley Fool

Topics Intellectual Property

Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market ↗

September 22, 2025

Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs.

Via Benzinga

Metsera Stock Surges 59% Pre-Market After Pfizer Confirms Acquisition – Here Are The Details ↗

September 22, 2025

The upfront purchase price of $47.50 per share implies a premium of 43% from Metsera’s closing share price on Friday.

Via Stocktwits

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio

September 22, 2025

From Pfizer Inc.

Via Business Wire

Trump Administration To Unveil Tylenol-Autism Review, Tout This Drug As Potential Treatment: Report ↗

September 22, 2025

Trump administration to announce concerns about Tylenol use in pregnancy and potential treatment for autism, in line with President's priority.

Via Benzinga

Topics Government

3 Bargain Stocks for Investors on a Budget ↗

September 21, 2025

If every one of your dollars counts, make sure you're getting the biggest possible bang for your buck.

Via The Motley Fool

Topics Economy

Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon ↗

September 20, 2025

There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels.

Via The Motley Fool

Topics Government Intellectual Property World Trade

What Is Considered a Good Stock Dividend? 3 Healthcare Stocks That Fit the Bill ↗

September 20, 2025

A high yield is only one part of the story when it comes to picking dividend stocks.

Via The Motley Fool

Topics Intellectual Property

Prediction: These Could Be the Best-Performing Value Stocks Through 2030 ↗

September 20, 2025

These stocks are bargains now. But they probably won't be by the end of this decade.

Via The Motley Fool

Topics Artificial Intelligence Intellectual Property

The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market

September 19, 2025

The global pharmaceutical sector stands at the precipice of a monumental transformation, driven by an unprecedented convergence of scientific breakthroughs, technological innovation, and evolving...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

CDC Ends Universal Covid Vaccine Recommendation; Moderna Skids ↗

September 19, 2025

Moderna stock toppled Friday after advisors to the CDC and Prevention ended the universal recommendation for Covid vaccines.

Via Investor's Business Daily

Stay informed about the most active stocks in the S&P500 index on Friday's session. ↗

September 19, 2025

Looking for the most active stocks in the S&P500 index on Friday? Dive into today's session and discover the stocks that are dominating the trading activity and setting the pace for the market.

Via Chartmill

Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections

September 19, 2025

Pharmaceutical giant Eli Lilly and Company (NYSE:LLY) is gearing up for a stellar third quarter of 2025, with analysts projecting massive earnings per share (EPS) and revenue growth. The optimistic...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

GLP-1 Titans Clash: Eli Lilly Challenges Novo Nordisk's Dominance in a Spiraling Market Battle

September 19, 2025

The pharmaceutical industry is witnessing an unprecedented showdown as Eli Lilly (NYSE: LLY) rapidly encroaches upon Novo Nordisk's (NYSE: NVO) long-held lead in the burgeoning GLP-1 (glucagon-like...

Via MarketMinute

Lilly's AI Gambit: TuneLab Poised to Reshape Biotech Drug Discovery Landscape

September 19, 2025

Eli Lilly and Company (NYSE: LLY) has unveiled its groundbreaking TuneLab Platform, an artificial intelligence (AI) and machine learning (ML) initiative designed to democratize advanced drug discovery...

Via MarketMinute

Topics Animal Testing Artificial Intelligence Intellectual Property

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.